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Methods
• Virtual patients were generated using a population physiology model [4].
Age, BMI and weight were used to allometrically scale organ weights and
cardiac output [4]. A virtual population of healthy Caucasian individuals
with a mean age of 39 years, (range 18-60) was generated.
• Validated equations were used for the calculation of volume of distribution
and processes regulating absorption, distribution and elimination [5-9].
• Physicochemical properties, in vitro apparent permeability, in vitro
intrinsic clearance and cytochrome P450 induction were obtained from
the literature.
• PK of ARVs was predicted using Simbiology (in MATLAB, version 2013b).
• Simulations for oral PK were first developed to validate the PBPK models
against available clinical data. The PBPK model for rilpivirine (RPV) was
then validated against the published PK of long-acting RPV to legitimise
the approach. Finally, the PK for IM administration of all the ARVs at
various dose and release rate combinations was simulated.
• For the first validation, oral absorption was simulated using a
compartmental absorption and transit model [6]. For IM depot
simulations, a discrete compartment was introduced to represent muscle
tissue containing the depot, and release of drug from the depot into the
blood plasma was assumed to follow dose-dependent first-order kinetics.
• Dose and release rate combinations of the 8 ARVs were optimised to give
predicted median plasma concentrations above the protein binding
corrected IC95 (PBIC95) or IC95 values 7- or 30-days after administration.Results
• The simulated PK parameters for oral administration were in
agreement with previously published clinical data (data not
shown).
• Validation of the PBPK model was subsequently conducted
against an existing long-acting IM formulation of RPV (600
mg; 100 mg mL-1) [10]. The mean values for AUC were 84.0
ng mL-1 h vs. 83.38 ± 33.34 ng mL-1 h, Cmax 96.7 ng mL
-1 vs.
86.73 ± 30.51 ng mL-1 and Ctrough 15.7 vs. 11.81 ± 6.3 ng mL
-1
for clinical versus predicted data with a predicted release
rate of 0.0011 ± 0.0001 h-1 for the clinical IM formulation
(Figure 2).
• A summary of the predicted values for AUC, Cmax and Cmin for
8 ARVs along with dose and release rate combinations
predicted to be optimal is shown in Table 1.
•Dolutegravir, efavirenz, emtricitabine, raltegravir, tenofovir
and RPV were predicted to be the suitable candidates for
monthly IM injection as shown in Figure 3.
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Figure 3. Simulated PK of IM sustained release NFs using PBPK modelling (a) Dolutegravir (b) Efavirenz (c) Emtricitabine (d) Raltegravir (e) RPV (f) Tenofovir. Mean Mean ± S.D. PBIC95/IC95
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Conclusion
• These data are theoretical and currently there is no evidence to confirm
or refute that these dose / release rate combinations can be achieved by
available technologies.
• Candidate ARVs with potential for reformulation into IM depot were
identified, providing the technological complexities associated with
reformulation can be overcome for these agents.
• Based on known clearance of RPV, monthly exposure from 250 mg (2.5
mL equivalent for latest existing formulation) is theoretically achievable
if release rate can be tuned to 0.002 h-1.
• PBPK modelling may be a useful tool for defining product
characteristics for sustained-release NF development.
Overview
• Antiretrovirals (ARVs) can find clinical application not only in the treatment of HIV
infection but also in its prevention. Recently pre-exposure prophylaxis (PrEP)
strategies have been developed for subjects who are at high risk of acquiring the
infection [1].
• Currently available oral formulations necessitate lifelong, daily dosing and a
suboptimal adherence, places the patient at risk of treatment failure and low rates
of protection for PrEP [2].
• The introduction of injectable sustained-release nano-formulations (NFs) could
represent a pharmacological option opening the possibility to simplify dosing
regimens, increase adherence, reduce the amount of drug consumed and thus
decrease the overall cost of the treatment and PrEP [3].
• Physiologically based pharmacokinetic (PBPK) modelling is the mathematical
description of anatomical, physiological and molecular processes defining drug
distribution (Figure 1b), through the integration of drug characteristics and
patient-specific factors (Figure 1a) [18].
• The aim of this study was to simulate the PK of intramuscular (IM) sustained
release NFs using PBPK modelling. Existing ARVs available as oral formulations
were assessed for compatibility. Theoretical target dose and release rate
combinations for once weekly and once monthly formats were identified.
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Figure 1. (a) Co-relation between some of the parameters involved in PBPK modelling.
(b) A diagrammatic representation of the anatomy of a virtual individual in the PBPK model.
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Figure 2. Validation of the PBPK strategy against clinical data for an 
existing RPV sustained-release formulation (600 mg; 100 mg mL-1).
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